These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6791675)

  • 21. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line.
    Twentyman PR; Bleehen NM
    Br J Cancer; 1975 Apr; 31(4):417-23. PubMed ID: 1156523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
    Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
    Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired multicellular-mediated resistance to alkylating agents in cancer.
    Kobayashi H; Man S; Graham CH; Kapitain SJ; Teicher BA; Kerbel RS
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3294-8. PubMed ID: 8475071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review.
    Marsh JC
    Cancer Res; 1976 Jun; 36(6):1853-82. PubMed ID: 773531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
    Higashihara J; Berens ME; Collins LA; Homesley HD; Welander CE
    Gynecol Oncol; 1993 Feb; 48(2):171-9. PubMed ID: 8428687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effects of cytostatic agents on short-term cultures (3H-uridine incorporation) and tissue cultures (cell counts) from human tumors (author's transl)].
    Mattern J; Wayss K; Volm M
    Arch Gynakol; 1974 May; 216(3):273-9. PubMed ID: 4135812
    [No Abstract]   [Full Text] [Related]  

  • 29. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
    Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
    Fujiya S; Yasuda M; Tahira K; Nakabayashi Y; Yoshioka M; Terashima Y; Hatiya S
    Gan To Kagaku Ryoho; 1985 May; 12(5):1080-7. PubMed ID: 3922310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
    Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
    Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current status of cancer chemotherapy.
    Montgomery JA
    Prog Drug Res; 1976; 20():465-90. PubMed ID: 796871
    [No Abstract]   [Full Text] [Related]  

  • 33. Starving tumors: inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies.
    Reutter M; Emons G; Gründker C
    Int J Gynecol Cancer; 2013 Jan; 23(1):34-40. PubMed ID: 23154267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
    Frankfurt OS; Seckinger D; Sugarbaker EV
    Anticancer Res; 1993; 13(4):947-52. PubMed ID: 8352564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proceedings: A comparison of tumour sensitivity to cytostatic agents during in vivo and in vitro culture.
    Bullen BR; Russell CW; Giles GR
    Br J Surg; 1976 Aug; 63(8):660. PubMed ID: 953488
    [No Abstract]   [Full Text] [Related]  

  • 36. [Human tumor clonogenic assay in human breast cancer].
    Kobayashi T; Kuraishi Y; Aiba K; Inoue K
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1566-72. PubMed ID: 3927846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo.
    Tropé C; Sigurdsson K
    Neoplasma; 1982; 29(3):309-14. PubMed ID: 7133226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
    Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
    Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.